Literature DB >> 22278964

Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations.

P Nuno Palma1, Maria João Bonifácio, Ana Isabel Loureiro, Patrício Soares-da-Silva.   

Abstract

Alchemical free energy simulations are amongst the most accurate techniques for the computation of the free energy changes associated with noncovalent protein-ligand interactions. A procedure is presented to estimate the relative binding free energies of several ligands to the same protein target where multiple, low-energy configurational substates might coexist, as opposed to one unique structure. The contributions of all individual substates were estimated, explicitly, with the free energy perturbation method, and combined in a rigorous fashion to compute the overall relative binding free energies and dissociation constants. It is shown that, unless the most stable bound forms are known a priori, inaccurate results may be obtained if the contributions of multiple substates are ignored. The method was applied to study the complex formed between human catechol-O-methyltransferase and BIA 9-1067, a newly developed tight-binding inhibitor that is currently under clinical evaluation for the therapy of Parkinson's disease. Our results reveal an exceptionally high-binding affinity (K(d) in subpicomolar range) and provide insightful clues on the interactions and mechanism of inhibition. The inhibitor is, itself, a slowly reacting substrate of the target enzyme and is released from the complex in the form of O-methylated product. By comparing the experimental catalytic rate (k(cat)) and the estimated dissociation rate (k(off)) constants of the enzyme-inhibitor complex, one can conclude that the observed inhibition potency (K(i)) is primarily dependent on the catalytic rate constant of the inhibitor's O-methylation, rather than the rate constant of dissociation of the complex.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278964     DOI: 10.1002/jcc.22926

Source DB:  PubMed          Journal:  J Comput Chem        ISSN: 0192-8651            Impact factor:   3.376


  16 in total

1.  Lead optimization mapper: automating free energy calculations for lead optimization.

Authors:  Shuai Liu; Yujie Wu; Teng Lin; Robert Abel; Jonathan P Redmann; Christopher M Summa; Vivian R Jaber; Nathan M Lim; David L Mobley
Journal:  J Comput Aided Mol Des       Date:  2013-09-26       Impact factor: 3.686

2.  Perspective: Alchemical free energy calculations for drug discovery.

Authors:  David L Mobley; Pavel V Klimovich
Journal:  J Chem Phys       Date:  2012-12-21       Impact factor: 3.488

3.  Separated topologies--a method for relative binding free energy calculations using orientational restraints.

Authors:  Gabriel J Rocklin; David L Mobley; Ken A Dill
Journal:  J Chem Phys       Date:  2013-02-28       Impact factor: 3.488

4.  Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Authors:  M J Bonifácio; L Torrão; A I Loureiro; P N Palma; L C Wright; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

5.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Authors:  José-Francisco Rocha; Amílcar Falcão; Ana Santos; Roberto Pinto; Nelson Lopes; Teresa Nunes; Lyndon C Wright; Manuel Vaz-da-Silva; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2014-06-14       Impact factor: 2.953

Review 6.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

7.  Detailed potential of mean force studies on host-guest systems from the SAMPL6 challenge.

Authors:  Lin Frank Song; Nupur Bansal; Zheng Zheng; Kenneth M Merz
Journal:  J Comput Aided Mol Des       Date:  2018-08-24       Impact factor: 3.686

8.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 9.  Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders.

Authors:  Zhiguo Ma; Hongming Liu; Baojian Wu
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

10.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.